PEER-REVIEWED PUBLICATIONS 

Dr Dinah Parums

1. Parums DV. Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance. Med Sci Monit. 2024; 30: e944600. doi: 10.12659/MSM.944600. PMID: 38557932. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10996429/
2. Parums DV. A Review of the Resurgence of Measles, a Vaccine-Preventable Disease, as Current Concerns Contrast with Past Hopes for Measles Elimination. Med Sci Monit, 2024; 30: e944436. doi: 10.12659/MSM.944436. PMID: 38525549. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946219/
3. Parums DV. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. Med Sci Monit, 2024; 30: e944204. doi: 10.12659/MSM.944204. PMID: 38425279. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913280/  
4. Parums DV. Editorial: Global Health Concerns as Vaccine-Preventable Infections Including SARS-CoV-2 (JN.1), Influenza, Respiratory Syncytial Virus (RSV), and Measles Continue to Rise. Med Sci Monit, 2024; 30: e943911. doi: 10.12659/MSM.943911. PMID: 38298093. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845785/  
5. Parums DV. A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future. Med Sci Monit. 2024; 30: e943912. doi: 10.12659/MSM.943912. PMID: 38281080. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10832303/
6. Parums DV. Editorial: Climate Change and the Spread of Vector-Borne Diseases, Including Dengue, Malaria, Lyme Disease, and West Nile Virus Infection. Med Sci Monit. 2024; 29: e943546. doi: 10.12659/MSM.943546. PMID: 38161310. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768291/
7. Parums DV. Editorial: Outbreaks of Post-Pandemic Childhood Pneumonia and the Re-Emergence of Endemic Respiratory Infections. Med Sci Monit. 2023; 29: e943312. doi: 10.12659/MSM.943312. PMID: 38037346. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702145/
8. Parums DV. Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared. Med Sci Monit. 2023; 29: e942960. doi: 10.12659/MSM.942960, PMID: 37908161. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626992/
9. Parums DV. Editorial: The Increasing Relevance of Case Reports in Medical Education and Clinical Practice – and How to Write Them. Am J Case Rep 2023; 24: e942670. doi:10.12659/AJCR.942670. PMID: 37777861. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556536/
10. Parums DV. Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution. Med Sci Monit. 2023; 29: e942672. doi:10.12659/MSM.942672. PMID: 37777859. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552569/
11. Parums DV. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2. Med Sci Monit. 2023;29:e942244. doi: 10.12659/MSM.942244. PMID: 37654205. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478578/
12. Parums DV. Editorial: First Regulatory Approval for Allogeneic Pancreatic Islet Beta Cell Infusion for Adult Patients with Type 1 Diabetes Mellitus. Med Sci Monit, 2023; 29: e941918. doi: 10.12659/MSM.941918. PMID: 37525584. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403990/
13. Parums DV. Editorial: Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). Updated Terminology for the Long-Term Effects of COVID-19. Med Sci Monit. 2023;29:e941595. doi: 10.12659/MSM.941595. PMID: 37392031. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321154/
14. Parums DV. Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness. Med Sci Monit. 2023;29:e941209. doi: 10.12659/MSM.941209. PMID: 37259578. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240961/
15. Parums DV. Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy. Med Sci Monit, 2023;29:e940911 doi: 10.12659/MSM.940911. PMID: 37122279. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161797/
16. Parums DV. Editorial: Effective Direct-Acting Antiviral Treatments Support Global and National Programs to Eliminate Hepatitis C. Med Sci Monit. 2023;29:e940519. doi: 10.12659/MSM.940519. PMID: 37002682. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075002/
17. Parums DV. Editorial: Global Surveillance of Highly Pathogenic Avian Influenza Viruses in Poultry, Wild Birds, and Mammals to Prevent a Human Influenza Pandemic. Med Sci Monit. 2023;29:e939968. doi: 10.12659/MSM.939968. PMID: 36855861. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987167/
18. Parums DV. Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread. Med Sci Monit. 2023;29:e939580. doi: 10.12659/MSM.939580. PMID: 36722047. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901170/
19. Parums DV. Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030. Med Sci Monit. 2023;29:e939357. doi: 10.12659/MSM.939357. PMID: 36587274. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814194/
20. Parums DV. Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic. Med Sci Monit, 2022; 28: e939088. doi: 10.12659/MSM.939088. PMID: 36453055. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724454/
21. Parums DV. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Med Sci Monit, 2022; 28: e938746. doi: 10.12659/MSM.938746. PMID: 36317327. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636839/
22. Parums DV. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir. Med Sci Monit 2022; 28:e938532. doi: 10.12659/MSM.938532. PMID: 36181334. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536144/
23. Parums DV. Editorial: Current Status of Non-Endemic Global Infections with the Monkeypox Virus. Med Sci Monit. 2022;28:e938203. doi: 10.12659/MSM.938203. PMID: 36047039. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447348/
24. Parums DV. Editorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 Pandemic. Med Sci Monit. 2022;28:e937927. doi: 10.12659/MSM.937927. PMID: 35909366. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354561/
25. Parums DV. Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2. Med Sci Monit. 2022;28:e937676. doi: 10.12659/MSM.937676. PMID: 35775166. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254723/
26. Parums DV. Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19. Med Sci Monit. 2022;28:e937048. doi: 10.12659/MSM.937048. PMID: 35490309. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069970/
27. Parums DV. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants. Med Sci Monit. 2022;28:e936523. doi: 10.12659/MSM.936523. PMID: 35228506. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897963/
28. Parums DV. Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2. Med Sci Monit 2022; 28:e936199. doi: 10.12659/MSM.936199. PMID: 35102132. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817616/
29. Parums DV. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients. Med Sci Monit. 2022;28:e935952. doi: 10.12659/MSM.935952. PMID: 34972812. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729033/
30. Parums DV. Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19. Med Sci Monit. 2021;27:e935624. doi: 10.12659/MSM.935624. PMID: 34848673. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647456/
31. Parums DV. Editorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems During the COVID-19 Pandemic? Med Sci Monit. 2021;27:e935299. doi: 10.12659/MSM.935299. PMID: 34719663. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570045/
32. Parums DV. Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD). Med Sci Monit. 2021;27:e935172. doi: 10.12659/MSM.935172. PMID: 34690345. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555443/
33. Parums DV. Editorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-19 Pandemic. Med Sci Monit. 2021;27:e935123. doi: 10.12659/MSM.935123. PMID: 34657930. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532519/
34. Parums DV. Editorial: Multisystem Inflammatory Syndrome in Adults (MIS-A) and the Spectrum of COVID-19. Med Sci Monit. 2021;27:e935005. doi: 10.12659/MSM.935005. PMID: 34629462. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518511/
35. Parums DV. Editorial: A Decline in Influenza During the COVID-19 Pandemic and the Emergence of Potential Epidemic and Pandemic Influenza Viruses. Med Sci Monit. 2021;27:e934949. doi: 10.12659/MSM.934949. PMID: 34602605. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499673/
36. Parums DV. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC). Med Sci Monit. 2021;27:e934854. doi: 10.12659/MSM.934854. PMID: 34565792. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482802/
37. Parums DV. Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19. Med Sci Monit. 2021;27:e934766. doi: 10.12659/MSM.934766. PMID: 34538868. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462125/
38. Parums DV. Editorial: The First Monoclonal Antibody Vaccine to Prevent Malaria Heralds a New Era of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP). Med Sci Monit. 2021;27:e934676. doi: 10.12659/MSM.934676. PMID: 34511592. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447852/
39. Parums DV. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Med Sci Monit. 2021;27:e934625. doi: 10.12659/MSM.934625. PMID: 34483336. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434768/
40. Parums DV. Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021. Med Sci Monit. 2021;27:e934514. doi: 10.12659/MSM.934514. PMID: 34456331. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415037/
41. Parums DV. Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines. Med Sci Monit. 2021;27:e934475. doi: 10.12659/MSM.934475. PMID: 34421116. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394590/
42. Parums DV. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19. Med Sci Monit. 2021;27:e934393. doi: 10.12659/MSM.934393. PMID: 34393218. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378223/
43. Parums DV. Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis. Med Sci Monit. 2021;27:e934292. doi: 10.12659/MSM.934292. PMID: 34366429. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362336/
44. Parums DV. Editorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19. Med Sci Monit. 2021;27:e934171. doi: 10.12659/MSM.934171. PMID: 34334785. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343537/
45. Parums DV. Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein. Med Sci Monit. 2021;27:e934077. doi: 10.12659/MSM.934077. PMID: 34305135. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323472/
46. Parums DV. Editorial: Maternal SARS-CoV-2 Infection and Pregnancy Outcomes from Current Global Study Data. Med Sci Monit. 2021;27:e933831. doi: 10.12659/MSM.933831. PMID: 34219126. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268975/
47. Parums DV. Editorial: Artificial Intelligence (AI) in Clinical Medicine and the 2020 CONSORT-AI Study Guidelines. Med Sci Monit. 2021;27:e933675. doi: 10.12659/MSM.933675. PMID: 34176921. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252890/
48. Parums DV. Editorial: Revised World Health Organization (WHO) Terminology for Variants of Concern and Variants of Interest of SARS-CoV-2. Med Sci Monit. 2021;27:e933622. doi: 10.12659/MSM.933622. PMID: 34149046. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230247/
49. Parums DV. Editorial: Registries and Population Databases in Clinical Research and Practice. Med Sci Monit. 2021;27:e933554. doi: 10.12659/MSM.933554. PMID: 34149048. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212698/
50. Parums DV. Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med Sci Monit. 2021;27:e933446. doi: 10.12659/MSM.933446. PMID: 34092779. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194290/
51. Parums DV. Editorial: COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C). Med Sci Monit. 2021;27:e933369. doi: 10.12659/MSM.933369. PMID: 34075014. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176784/
52. Parums DV. Editorial: 2021 European Society for Medical Oncology (ESMO) Recommendations on Laboratory Diagnostics for RET Gene Fusions and Mutations: A New Era in Targeted Therapy for RET-Altered Solid Tumors. Med Sci Monit. 2021;27:e933206. doi: 10.12659/MSM.933206. PMID: 34024902. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162049/
53. Parums DV. Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections. Med Sci Monit. 2021;27:e932915. doi: 10.12659/MSM.932915. PMID: 33942804. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106254/
54. Parums DV. Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). Med Sci Monit. 2021;27:e932899. doi: 10.12659/MSM.932899. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086413/
55. Parums DV. Editorial. The Role of the Pathologist in the Era of Personalized Medicine. SM J Clin Pathol. 2016;1(1):1003. Available from: https://www.jsmcentral.org/sm-clinical-pathology/fulltext_smjcp-v1-1003.pdf
56. Parums DV. Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc). 2014;50(7):503-25. doi: 10.1358/dot.2014.50.7.2185913. PMID: 25101332. Available from: https://www.academia.edu/10248939/Current_Status_of_Targeted_Therapy_in_Non_Small_Cell_Lung_Cancer_NSCLC_
57. Parums DV. Invited Review: Status of Immune Therapy in Non Small-Cell Lung Cancer (NSCLC). Drugs Future 2014;39(7): 469-475. doi: 10.1358/dof.2014.39.7.2185935. Available from: https://www.academia.edu/14478210/Status_of_Immune_Therapy_in_Non_Small_Cell_Lung_Cancer_NSCLC_
58. Donovan MJ, Kotsianti A, Bayer-Zubek V, Verbel D, Teverovskiy M, Cordon-Cardo C, Costa J, Greco FA, Hainsworth JD, Parums DV. A systems pathology model for predicting overall survival in patients with refractory, advanced non small-cell lung cancer treated with gefitinib. Eur J Cancer. 2009 May;45(8):1518-26. doi: 10.1016/j.ejca.2009.02.004. Epub 2009 Mar 9. PMID: 19272767. Available from: https://www.ejcancer.com/article/S0959-8049(09)00091-4/fulltext
59. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn Jr PA, Franklin WA. Epidermal Growth Factor Immunohistochemistry: Comparison of Antibodies and Cut-off Points to Predict Benefit from Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small Cell Lung Cancer. 2008 Mar 1;112(5):1114-21. doi: 10.1002/cncr.23282. PMID: 18219661. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355966/
60. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums DV, Botwood, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 1;24(31):5034-42. doi: 10.1200/JCO.2006.06.3958. PMID: 17075123. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.2006.06.3958
61. Torsney E, Charlton R, Parums DV, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002 Sep;51(9):464-70. doi: 10.1007/pl00012413. PMID: 12365720. Available from: https://link.springer.com/article/10.1007/PL00012413
62. Katz SD, Parums DV. Sympathetic activation by sildenafil. Circulation. 2001 Nov 27;104(22):E119-20. PMID: 11723034. Available from: https://www.ahajournals.org/doi/epub/10.1161/circ.104.22.e119
63. Ray-Chaudhuri N, Kine DA, Tijani SO, Parums DV, Cartlidge N, Strong NP, Dayan MR. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002 May;86(5):530-2. doi: 10.1136/bjo.86.5.530. PMID: 11973248. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771122/
64. Luckraz H, Parums DV, Dunning J. Reverse saphenous interposition vein graft repair of a giant atherosclerotic aneurysm of the left anterior descending coronary artery. J Thorac Cardiovasc Surg. 2002 Apr;123(4):817-20. doi: 10.1067/mtc.2002.121290. PMID: 11986613. Available from: https://www.jtcvs.org/article/S0022-5223(02)80294-X/fulltext
65. De Soyza AG, Dark JH, Parums DV, Curtis A, Corris PA. Donor-acquired small cell lung cancer following pulmonary transplantation. Chest. 2001 Sep;120(3):1030-1. doi: 10.1378/chest.120.3.1030. PMID: 11555546. Available from: https://journal.chestnet.org/article/S0012-3692(15)50193-1/fulltext
66. Arthur H, Torsney E, Ure J, Smith A, Wilson D, Charlton RG, Parums DV, Jowett T, Burn J, Diamond A. Endoglin, an ancillary TGF Beta Receptor, is Required for Extraembryonic Angiogenesis and Plays a Key Role in Heart Development. Dev Biol. 2000 Jan 1;217(1):42-53. doi: 10.1006/dbio.1999.9534. PMID: 10625534. Available from: https://www.sciencedirect.com/science/article/pii/S0012160699995349
67. Pagano D, Townend JN, Parums DV, Bonser RS, Camici PG. Hibernating Myocardium: Morphological Correlates of Inotropic Stimulation and Glucose Uptake. 2000 Apr;83(4):456-61. doi: 10.1136/heart.83.4.456. PMID: 10722551. Available from: https://heart.bmj.com/content/83/4/456.long
68. Kumar RP, Smith DA, Hilton CJ, Parums DV. A Case of Epithelioid Haemangioendothelioma (EHE) of the Lung with Bronchial Brushing Cytology. 1999 Apr;10(2):132-6. doi: 10.1046/j.1365-2303.1999.00111.x. PMID: 10211620. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2303.1999.00111.x
69. Crilley JG, Owens WA, Parums DV. A Dissection with a Difference: An Unusual Case of Ascending Aortic Dissection Secondary to Granulomatous Aortitis. Hosp Med. 1998 Nov;59(11):892-3. PMID: 10197126. https://eurekamag.com/research/045/057/045057665.php
70. Parums DV. Invited Commentary: Histiocytosis X. 1998 Apr;53(4):322-3. doi: 10.1136/thx.53.4.322. PMID: 9741379. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1745190/
71. Gorog DA, Rakhit R, Parums DV, Laffan M, Davies GJ. Raised Factor VIII is Associated with Coronary Thrombotic Events. 1998 Oct;80(4):415-7. doi: 10.1136/hrt.80.4.415. PMID: 9875127. Available from: https://heart.bmj.com/content/80/4/415.long
72. Marchbank AJ, Parums DV, Westaby S. Tricuspid valve repair in a mountaineer. Ann Thorac Surg. 1998 Feb;65(2):537-9. doi: 10.1016/s0003-4975(97)01355-6. PMID: 9485262. Available from: https://www.annalsthoracicsurgery.org/article/S0003-4975(97)01355-6/fulltext
73. Leonard A, Corris P, Parums, DV. Amiodarone pulmonary toxicity. 1997 Jun 21;314(7097):1831-2. doi: 10.1136/bmj.314.7097.1831b. PMID: 9224103. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2126921/
74. Walton LJ, Powell JT, Parums DV. Unrestricted Usage of Immunoglobulin Heavy Chain Genes in B Cells Infiltrating the Wall of Atherosclerotic Abdominal Aortic Aneurysms. 1997 Nov;135(1):65-71. doi: 10.1016/s0021-9150(97)00152-4. PMID: 9395274. Available from: https://www.atherosclerosis-journal.com/article/S0021-9150(97)00152-4/pdf
75. Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, Parums DV, Yacoub MH, Polak JM. Inducible Nitric Oxide Synthase is Present within Human Atherosclerotic Lesions and Promotes the Formation and Activity of Peroxynitrite. Lab Invest. 1996 Jul;75(1):77-85. PMID: 8683942. Available from: https://eurekamag.com/research/031/900/031900261.php
76. Parums DV, Ashton MD, Mason JC, Haskard DO. Thy-1 expression by new vessels associated with atherosclerosis. J Pathol 1996; 179:A46-A46. ISSN: 0022-3417.
77. Kennedy P, Parry AJ, Parums DV, Pillai R. Myxoma of the aortic valve. Ann Thorac Surg. 1995 May;59(5):1221-3. doi: 10.1016/0003-4975(94)00969-e. PMID: 7733728. Available from: https://www.annalsthoracicsurgery.org/article/0003-4975(94)00969-E/pdf
78. Ramshaw AL, Roskell DE, Parums DV. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol. 1994 Aug;47(8):721-7. doi: 10.1136/jcp.47.8.721. PMID: 7962625. Available from: https://jcp.bmj.com/content/jclinpath/47/8/721.full.pdf
79. Parums DV. Invited review: The Arteritides. 1994 Jul;25(1):1-20. doi: 10.1111/j.1365-2559.1994.tb00593.x. PMID: 7959641. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1994.tb00593.x
80. Potter CG, Ramshaw AL, Stickland JE, Parums DV, McGee JO’D. Quantification of specific mRNA by flat-bed scintillation counting of dual-labelled dot blots. 1993 Oct;15(4):738-43. PMID: 8251177.
81. Wood KM, Cadogan MD, Ramshaw AL, Parums DV. The distribution of adhesion molecules in human atherosclerosis. 1993 May;22(5):437-44. doi: 10.1111/j.1365-2559.1993.tb00157.x. PMID: 7688340. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1993.tb00157.x
82. Ramshaw AL, Parums DV. The distribution of adhesion molecules in chronic periaortitis. 1994 Jan;24(1):23-32. doi: 10.1111/j.1365-2559.1994.tb01267.x. PMID: 7511559. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1994.tb01267.x
83. Paul J, Baigrie C, Parums DV. A fatal case of disseminated infection with the turtle bacillus, Mycobacterium chelonae. J Clin Pathol. 1992 Jun;45(6):528-30. doi: 10.1136/jcp.45.6.528. PMID: 1624602. Available from: https://jcp.bmj.com/content/jclinpath/45/6/528.full.pdf
84. Davies AH, Parums DV. Storage of donor long saphenous vein. J Cardiovasc Surg (Torino). 1992 Jan-Feb;33(1):92-7. PMID: 1545005.
85. Ramshaw AL, Parums DV. Combined immunohistochemical and immunofluorescence method to determine the phenotype of proliferating cell populations. J Clin Pathol. 1992 Nov;45(11):1015-7. doi: 10.1136/jcp.45.11.1015. PMID: 1485903. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC495036/
86. Parums DV, Choudhury RP, Shields SA, Davies AH. Characterization of inflammatory cells associated with idiopathic retroperitoneal fibrosis. Br J Urol. 1991 Jun;67(6):564-8. doi: 10.1111/j.1464-410x.1991.tb15216.x. PMID: 2070198. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1464-410X.1991.tb15216.x
87. McKee G, Parums DV. False positive cytodiagnosis in fibrosing alveolitis. Acta Cytol. 1990 Jan-Feb;34(1):105-7. PMID: 2296835.
88. Cawthorn SJ, Parums DV, Gibbs NM, A’Hern RP, Caffarey SM, Broughton CIM, Marks CG. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal carcinoma. 1990 May 5;335(8697):1055-9. doi: 10.1016/0140-6736(90)92631-q. PMID: 1691810. Available from: https://www.thelancet.com/journals/lancet/article/PII0140-6736(90)92631-Q/fulltext
89. Parums DV, Dunn DC, Dixon AK, Mitchinson MJ. Characterization of inflammatory cells in a patient with chronic periaortitis. Am J Cardiovasc Pathol. 1990;3(2):121-9. PMID: 2264985.
90. Parums DV. Inflammatory mediators and atherosclerosis. Biochem Soc Trans. 1990 Dec;18(6):1069-72. doi: 10.1042/bst0181069. PMID: 2088809. Available from: https://portlandpress.com/biochemsoctrans/article/18/6/1069/82423/Inflammatory-mediators-in-atherosclerosis
91. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized LDL and ceroid in chronic periaortitis. Arch Pathol Lab Med. 1990 Apr;114(4):383-7. PMID: 2322097.
92. Parums DV. The spectrum of chronic periaortitis. 1990 May;16(5):423-31. doi: 10.1111/j.1365-2559.1990.tb01541.x. PMID: 2193863. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1990.tb01541.x
93. Ramshaw AL, Parums DV. Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis. 1990 Dec;17(6):543-52. doi: 10.1111/j.1365-2559.1990.tb00794.x. PMID: 2076887. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1990.tb00794.x
94. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70 (CD31): A new monoclonal antibody that detects vascular endothelium-associated antigen on routinely processed tissue sections. J Clin Pathol. 1990 Sep;43(9):752-7. doi: 10.1136/jcp.43.9.752. PMID: 2212067. Available from: https://jcp.bmj.com/content/jclinpath/43/9/752.full.pdf
95. Parums DV. Studies on Inflammation in Atherosclerosis. PhD thesis. University of Cambridge, 1987.
96. Parums DV, Chadwick DR, Mitchinson MJ. The localisation of immunoglobulin in chronic periaortitis. 1986 Aug;61(2):117-23. doi: 10.1016/0021-9150(86)90070-5. PMID: 3530262. Available from: https://www.atherosclerosis-journal.com/article/0021-9150(86)90070-5/pdf
97. Parums DV, Mitchinson MJ. Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. 1981 Jan-Feb;38(1-2):211-6. doi: 10.1016/0021-9150(81)90118-0. PMID: 7470201.

Dr Dinah Parums. A combined immunohistochemistry and immunofluorescence method showing CD31 positive endothelial cells (green) and HLA-DR positive cells (red) with ‘activated’ endothelial cells yellow.

Dr Dinah Parums. Photomicrograph of chronic periaortitis – advanced atherosclerosis, medial thinning and chronic adventitial inflammation.